An Active Surveillance, Post Authorization Safety Study (PASS) to Estimate Incidence Rates of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among all Patients Treated with Ruxience for Rheumatoid Arthritis (RA) within the British Society for Rheumatology Biologics Register Rheumatoid Arthritis (BSRBR RA)

First published: 21/10/2020

Last updated: 03/09/2024

Study Finalised

Administrative details

EU PAS number

EUPAS37688

Study ID

41909

DARWIN EU® study

No

Study countries

United Kingdom

Study description

To estimate incidence rates of infections, including serious infections, malignancies, cardiovascular events, and events associated with use during pregnancy among patients with rheumatoid arthritis in the BSRBR-RA who initiate Ruxience.

Study status

Finalised

Research institutions and networks

Institutions

Pfizer

First published: 01/02/2024

Last updated: 01/02/2024

Institution

University of Manchester

United Kingdom

First published: 01/02/2024

Last updated: 01/02/2024

Institution | Educational Institution

Centre for Musculosketal Research, University of Manchester

Contact details

Study institution contact

Cynthia de Luise cynthia.deluise@pfizer.com

Study contact

cynthia.deluise@pfizer.com

Primary lead investigator

Cynthia de Luise

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 14/10/2020

Study start date

Planned: 31/05/2021

Actual: 31/05/2021

Data analysis start date

Planned: 31/12/2023

Date of final study report

Planned: 22/02/2024

Actual: 03/03/2024

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Pfizer, Inc.

Study protocol

B3281011_PROTOCOL AND APPROVAL_BSRBR PASS Ruxience_V1.0_14OCT2020.pdf (5.56 MB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Disease epidemiology

Drug utilisation

Main study objective:

To estimate incidence rates of infections, including serious infections, malignancies, cardiovascular events, and events associated with use during pregnancy among patients with rheumatoid arthritis in the BSRBR-RA who initiate Ruxience.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

RUXIENCE

Study drug International non-proprietary name (INN) or common name

RITUXIMAB

Medical condition to be studied

Rheumatoid arthritis

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Special population of interest

Pregnant women

Estimated number of subjects

50

Study design details

Data analysis plan

Descriptive summaries of Ruxience exposed patients and crude incidence rates and 95% confidence intervals of safety events of interest.

Documents

Study report

B3281011_NI STUDY REPORT_V.1_22FEB2024.pdf (252.26 KB)

B3281011_NON-INTERVENTIONAL STUDY REPORT ABSTRACT_22FEB2024.pdf (106.65 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Data sources (types)

Disease registry

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No